The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These ...

Understanding the factors associated with geographic atrophy progression is key to identifying those who may benefit from treatment.

Researchers analyzed longitudinal changes in substructure brain volumes after menopause in women with multiple sclerosis.

Muscle atrophy is when muscles shrink from lack of use. It can occur due to an injury, a neurological condition, or from a ...

Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Researchers have identified two compounds capable of repairing the protective myelin sheath damaged by multiple sclerosis, a major advance toward reversing nerve injury rather than just slowing it.

Shares of Alterity Therapeutics Ltd (NASDAQ:ATHE) climbed 3.3% in premarket trading on Thursday after the company unveiled ...

Investing.com -- Alterity Therapeutics Ltd (NASDAQ:ATHE) stock rose 3.3% in premarket trading Thursday following the company’s presentation of positive data from its Phase 2 clinical trial for ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

At least, that is what doctors thought the first day he was in the hospital in late June.